COVID-19 Update from HemoSonics

News & Events

Find the latest news and updates from HemoSonics.

April 13, 2020

COVID-19 Update from HemoSonics

Consistent with our company’s mission to deliver clinical tools that provide actionable information in the critical care setting resulting in better care for patients, HemoSonics is closely monitoring the COVID-19 pandemic and evaluating how the Quantra® System may help in the effort to conserve valuable blood supplies, support protection of healthcare providers, and improve patient outcomes.

Recent clinical reports have shown that patients with severe COVID-19 infection can develop a coagulopathy that is likely triggered by the acute inflammatory response. This is reflected as abnormal values of laboratory coagulation parameters consistent with disseminated intravascular coagulation (DIC). These include prolonged clotting times, high D-dimer levels, thrombocytopenia and low fibrinogen levels. DIC is a rapidly evolving condition that, if not properly recognized and addressed, can quickly lead to the formation of microvascular thrombi and/or hemorrhage.

“While we are very early in this work, we are committed to doing our part in the fight against this global pandemic,” said Bob Roda, President and CEO of HemoSonics.

HemoSonics has responded to requests from several clinical sites in Europe and is supporting their investigations to understand the potential utility of the Quantra System for the evaluation of blood coagulation status in COVID-19 patients at the point-of-care. The Quantra Hemostasis Analyzer and its closed system cartridges (QPlus® and QStat® Cartridges) require no blood manipulation after collection which minimizes potential biological exposure to healthcare professionals.

Quantra COVID19

For further clinical information, please contact us at clinical@hemosonics.com.

This communication contains information on products which is targeted to a wide range of audiences and could contain product details or information not otherwise accessible or valid in your country. Please refer to the applicable approved instructions for use.

Visit our Blog for Additional information

Tags: